US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alk Abello AS

26.99

0.0000

Volume:- -

Turnover:- -

Market Cap:5.97B

PE:72.51

High:26.99

Open:26.99

Low:26.99

Close:26.99

Loading ...

Overview Company News Filings

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

ALK enters into neffy® co-promotion agreement in the USA

Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025

ITULAZAX® tree pollen tablet approved for treatment of children in Europe

Grant of share-based long-term incentive instruments to members of the Board of Management and key employees

ACARIZAX® approved in Canada for treatment of young children

U.S. FDA Approves Label Expansion for ALK's ODACTRA® (House Dust Mite Allergen Tablet) for Sublingual Use as Immunotherapy to Now Include Children with House Dust Mite Allergy

FDA approves ODACTRA® for the treatment of house dust mite allergy in young children

Alk-Abello AS (AKBLF) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion

3 Stocks Estimated To Be Trading At Discounts Of 26% To 44%

Simply Wall St.

3 Stocks That May Be Trading Below Estimated Value

Simply Wall St.

Positive results advance peanut tablet to phase II development

Alk-Abello AS (AKBLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Margins

3 Stocks That May Be Trading At A Discount Of Up To 41.4%

Simply Wall St.

ARS Pharmaceuticals announces agreement with ALK to commercialize neffy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AKBLF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AKBLF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AKBLF\",,,,,undefined,":{"symbol":"AKBLF","market":"US","secType":"STK","nameCN":"Alk Abello AS","latestPrice":26.99,"timestamp":1748894400000,"preClose":26.99,"halted":0,"volume":0,"delay":15,"floatShares":131392384,"shares":221189247,"eps":0.372211,"marketStatus":"Closed","change":0,"latestTime":"06-02 16:00:00 EDT Delay","open":26.99,"high":26.99,"low":26.99,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.372211,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1748937600000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":26.99,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AKBLF\",,,,,undefined,":{"symbol":"AKBLF","floatShares":131392384,"roa":"10.44%","roe":"18.08%","lyrEps":0.325905,"shares":221189247,"dividePrice":0,"high":26.99,"amplitude":0,"preClose":26.99,"low":26.99,"week52Low":19.9,"pbRate":"7.15","psRate":"7.11","week52High":27.05,"institutionHeld":0,"latestPrice":26.99,"eps":0.372211,"divideRate":0,"volume":0,"delay":15,"ttmEps":0.372211,"open":26.99,"prevYearClose":22.35,"prevWeekClose":26.99,"prevMonthClose":26.99,"prevQuarterClose":19.9,"fiveDayClose":25.95,"twentyDayClose":19.9,"sixtyDayClose":21.35},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AKBLF\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532481668","title":"ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians","url":"https://stock-news.laohu8.com/highlight/detail?id=2532481668","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532481668?lang=en_us&edition=fundamental","pubTime":"2025-05-02 20:00","pubTimestamp":1746187200,"startTime":"0","endTime":"0","summary":"Agreement builds on landmark licensing deal between ARS Pharma and ALK-Abelló A/S, which provided ARS Pharma with $145 million upfront and ALK with commercialization rights to neffy in Canada, United Kingdom, European Union and certain other countries outside the United States. New partnership expands ARS Pharma’s direct promotional efforts to nearly 20,000 healthcare providers, reaching key pediatricians ahead of the back-to-school season. “As a result of broad coverage from leading pharmaceutical benefit managers and health plans, millions of patients nationwide now have improved access to neffy,” said Richard Lowenthal, Co-Founder, President, and CEO of ARS Pharma. “This partnership extension with ALK allows us to efficiently reach healthcare professionals who represent about 55% of all community-use epinephrine prescriptions in the United States. By expanding direct promotion with ALK, the global leader in allergy immunotherapy  with substantial experience in the allergy space, we ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ars-pharmaceuticals-announces-co-promotion-120000254.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4104","BK4588","LU0054578231.USD","AKBLF","BK4500","BK4008","BK4585","LU0053671581.USD","LU2065731478.USD","AIT","SPRY","LU1878469433.USD","BK4007","ALK"],"gpt_icon":0},{"id":"2532184819","title":"ALK enters into neffy® co-promotion agreement in the USA","url":"https://stock-news.laohu8.com/highlight/detail?id=2532184819","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532184819?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:59","pubTimestamp":1746187140,"startTime":"0","endTime":"0","summary":"Co-promotion with ARS Pharma based on cost sharing and performance-based revenue sharing.ALK to accelerate build-up of its US paediatric sales channel in a balanced way.Agreement does not change ALK’s revenue and earnings outlook for 2025.ALK  today announced a 4-year agreement with US-based ARS Pharmaceuticals, Inc.  to co-promote the neffy adrenaline  nasal spray to up to 9,000 named paediatricians in the USA. These paediatricians currently account for close to 10% of all adrenaline auto-injector prescriptions in the USA.Commenting on the new agreement, ALK's CEO Peter Halling said: “We are excited about expanding our partnership with ARS Pharma, which we firmly consider a win-win situation for all parties. More children, caregivers, and prescribers in the USA get access to an effective and needle-free anaphylaxis treatment. Although the agreement initially will have a limited financial impact for ALK, we are strengthening our capabilities in the USA. This may also support our respir","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alk-enters-neffy-co-promotion-115900482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4008","BK4588","BK4500","EBIT","SPRY","ALK","AKBLF","BK4139","BK4585"],"gpt_icon":0},{"id":"2531433752","title":"Invitation to the presentation of ALK’s first quarter 2025 results on Tuesday, 6 May 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531433752","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531433752?lang=en_us&edition=fundamental","pubTime":"2025-04-29 22:39","pubTimestamp":1745937540,"startTime":"0","endTime":"0","summary":"ALK  will publish its results for the first quarter of 2025 in the morning on Tuesday, 6 May 2025.Later on the same day, the company will host a presentation for investors and analysts at 11:00 a.m. CEST, where ALK’s management will comment on the results and outlook and be available for questions.ALK will be represented by Peter Halling, President & CEO, Claus Steensen Slje, CFO and Per Plotnikof, VP, Head of IR.The meeting will be audio webcasted live and be available for replay on ALK’s website.The presentation will be available on ALK's website shortly before the meeting starts.Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525. About ALKALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hrsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Fi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/invitation-presentation-alk-first-quarter-143900393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","BK4585","BK4588","AKBLF","ALK","BK4500","BK4008"],"gpt_icon":0},{"id":"2529682357","title":"ITULAZAX® tree pollen tablet approved for treatment of children in Europe","url":"https://stock-news.laohu8.com/highlight/detail?id=2529682357","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529682357?lang=en_us&edition=fundamental","pubTime":"2025-04-23 21:58","pubTimestamp":1745416680,"startTime":"0","endTime":"0","summary":"ALK  today announced that its European regulatory filing for ITULAZAX  for treatment of young children and adolescents aged five to 17 has been approved by the health authorities in 17 EU countries via a type II variation procedure. First market introductions are expected to follow in the coming months ahead of the 2025/2026 initiation season for new patients starting treatment on pollen allergy tablets.Executive Vice President of R&D, Henriette Mersebach , says: “We are very pleased with the European health authorities' approval which allows us to provide this important treatment option to children and adolescents whose lives are impaired by uncontrolled tree pollen-induced respiratory allergy. Today’s approval marks another significant milestone in our continuous efforts to make our respiratory tablets available to all age groups in all relevant markets\".The tree tablet, branded ITULAZAX in Europe and ITULATEK in Canada, has, until now, been approved by 22 countries for adult patient","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/itulazax-tree-pollen-tablet-approved-135800319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4196","AKBLF","BK4007","MD"],"gpt_icon":0},{"id":"2524058269","title":"Grant of share-based long-term incentive instruments to members of the Board of Management and key employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2524058269","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524058269?lang=en_us&edition=fundamental","pubTime":"2025-04-03 22:24","pubTimestamp":1743690240,"startTime":"0","endTime":"0","summary":"ALK : According to the company’s remuneration policy adopted at the company's Annual General Meeting on 14 March 2024 and in line with the company’s usual practice, the Board of Directors has passed a resolution to grant up to a total of 250,000 share-based instruments for the purpose of the company’s long-term incentive plan  for the Board of Management and key employees for 2025.The share options are subject to the fulfilment of financial and/or non-financial key indicator with a defined threshold, below which there would be no payout, and with the opportunity to perform above target. As in previous years, in case of performance above target, a defined multiplier is used that can increase the payout by up to 100%.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/grant-share-based-long-term-142400956.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AKBLF","BK4007"],"gpt_icon":0},{"id":"2517143338","title":"ACARIZAX® approved in Canada for treatment of young children","url":"https://stock-news.laohu8.com/highlight/detail?id=2517143338","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517143338?lang=en_us&edition=fundamental","pubTime":"2025-03-07 21:34","pubTimestamp":1741354440,"startTime":"0","endTime":"0","summary":"ALK  today announced that Health Canada has approved ALK’s ACARIZAX tablet for use in children, aged five to 11, with house dust mite  allergy. ACARIZAX is now indicated for treatment of moderate to severe HDM-induced allergic rhinitis, with or without conjunctivitis, in children, adolescents, and adults in Canada aged five to 65.Outside Europe, Canada is one of the most important markets for ALK’s respiratory tablet portfolio with sales growing continuously by double digits. The expanded ACARIZAX label is expected to further benefit market uptake in Canada.The approval is based on the largest-ever paediatric AIT Phase 3 clinical trial, MT-12, involving 1,460 children aged five to 11 in North America and Europe. The trial demonstrated efficacy and safety of the treatment in children, and results were recently published in the scientific journal, The Lancet Regional Health – Europe.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acarizax-approved-canada-treatment-young-133400102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","AKBLF","MD","BK4196"],"gpt_icon":0},{"id":"2514321654","title":"U.S. FDA Approves Label Expansion for ALK's ODACTRA® (House Dust Mite Allergen Tablet) for Sublingual Use as Immunotherapy to Now Include Children with House Dust Mite Allergy","url":"https://stock-news.laohu8.com/highlight/detail?id=2514321654","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514321654?lang=en_us&edition=fundamental","pubTime":"2025-02-28 21:00","pubTimestamp":1740747600,"startTime":"0","endTime":"0","summary":"- ODACTRA is now indicated to treat house dust mite -induced allergic rhinitis, with or without conjunctivitis, in children ages 5 through 11 years, in addition to patients 12 through 65 years of age –。- House dust mites are a common cause of allergies in children and can cause symptoms year-round1 -. BEDMINSTER, N.J., Feb. 28, 2025 /PRNewswire/ -- ALK  today announced that the U.S. Food and Drug Administration  expanded its indication of ODACTRA  for the treatment of house dust mite -induced allergic rhinitis, with or without conjunctivitis, to now include children ages 5 through 11 years, in addition to patients 12 through 65 years of age.2ODACTRA is an allergy immunotherapy indicated to treat HDM-induced allergic rhinitis and is administered sublingually as a small tablet that dissolves under the tongue. Having this option available for parents with children who meet the treatment requirements is so important, as many children at this age can have a challenging time with other presc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/u-fda-approves-label-expansion-130000839.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-fda-approves-label-expansion-130000839.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4008","BK4500","BK4585","BK4007","AKBLF","ALK"],"gpt_icon":0},{"id":"2514370493","title":"FDA approves ODACTRA® for the treatment of house dust mite allergy in young children","url":"https://stock-news.laohu8.com/highlight/detail?id=2514370493","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514370493?lang=en_us&edition=fundamental","pubTime":"2025-02-28 04:51","pubTimestamp":1740689460,"startTime":"0","endTime":"0","summary":"ALK  today announced that the US Food and Drug Administration  has approved ALK’s ODACTRA tablet for use in young children with house dust mite  allergy. ODACTRA is now indicated to treat HDM-induced allergic rhinitis, with or without conjunctivitis, in children aged five through 11, in addition to patients aged 12 through 65.ODACTRA is an allergy immunotherapy  tablet which dissolves under the tongue and helps patients reduce their allergy symptoms and their reliance on symptomatic medication.The FDA approval is an important step in ALK’s efforts to make all its respiratory tablets available for all age groups – children, adolescents, and adults - in all relevant markets.The data that formed the basis for the approval includes results from the largest-ever paediatric AIT Phase 3 clinical trial, MT-12, which involved 1,460 children in North America and Europe. The trial demonstrated efficacy and safety of the treatment in children, and the results were recently published in the reputab","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-approves-odactra-treatment-house-205100663.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MD","BK4196","BK4007","LU1878469433.USD","BK4104","LU2065731478.USD","AKBLF","LU0053671581.USD","AIT","LU0054578231.USD"],"gpt_icon":0},{"id":"2512494563","title":"Alk-Abello AS (AKBLF) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2512494563","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512494563?lang=en_us&edition=fundamental","pubTime":"2025-02-20 15:03","pubTimestamp":1740034991,"startTime":"0","endTime":"0","summary":"Full Year Revenue: Up 15%, exceeding DKK5.5 billion.European Tablet Sales Growth: Increased by 32% in Q4 and 31% for the full year.Operating Margin: Q4 ended at 14%, full year EBIT margin increased from 14% to 20%.Full Year Earnings Growth: Improved by 65% in local currencies.Gross Margin: 64.2%, an improvement of more than 1 percentage point.Free Cash Flow: Negative DKK204 million due to DKK1 billion upfront payment for Neffy license.Capacity Costs: Increased by 4% to DKK2.5 billion.SCIT and SLIT Drops Revenue Growth: Up 6% globally.Other Products Revenue Growth: Increased by 7% globally.2025 Revenue Growth Projection: Expected to increase by 9% to 13%.2025 EBIT Margin Projection: Expected to increase by 5 percentage points to around 25%.GuruFocus has detected 7 Warning Sign with TRMB.For the complete transcript of the earnings call, please refer to the full earnings call transcript.2024 was a record year for Alk-Abello AS , with revenue up 15% and earnings improving by 65% in local c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alk-abello-akblf-q4-2024-070311391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AKBLF"],"gpt_icon":0},{"id":"2505276343","title":"3 Stocks Estimated To Be Trading At Discounts Of 26% To 44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505276343","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505276343?lang=en_us&edition=fundamental","pubTime":"2025-01-22 12:05","pubTimestamp":1737518755,"startTime":"0","endTime":"0","summary":"As global markets experience fluctuations with cooling inflation and strong bank earnings propelling U.S. stocks higher, investors are increasingly focused on identifying opportunities amidst these shifting conditions. In this environment, finding undervalued stocks can be a compelling strategy, as they may offer potential value when market sentiment is volatile and certain sectors outperform others.Overview: Mets Board Oyj operates globally in the folding boxboard, fresh fibre linerboard, and market pulp sectors, with a market capitalization of 1.69 billion.Operations: The company's revenue from its folding boxboard, fresh fibre linerboard, and market pulp businesses amounts to 1.92 billion.Mets Board Oyj is trading at 4.57, significantly below its estimated fair value of 7.03, suggesting it may be undervalued based on cash flows. Despite a forecasted low return on equity of 11.3% in three years, earnings are expected to grow significantly at 52.5% per year, outpacing the Finnish mark","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-stocks-estimated-trading-discounts-040555342.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","AKBLF"],"gpt_icon":0},{"id":"2493721186","title":"3 Stocks That May Be Trading Below Estimated Value","url":"https://stock-news.laohu8.com/highlight/detail?id=2493721186","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493721186?lang=en_us&edition=fundamental","pubTime":"2024-12-24 12:07","pubTimestamp":1735013223,"startTime":"0","endTime":"0","summary":"In the current climate, global markets are experiencing volatility with U.S. stocks facing declines due to cautious Federal Reserve commentary and political uncertainties, while European and Asian indices also reflect investor apprehension over interest rate outlooks. Amid these fluctuations, identifying stocks that may be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on market inefficiencies. A good stock in this context is one that demonstrates strong fundamentals but is temporarily undervalued due to broader market sentiments rather than company-specific issues.Operations: The company's revenue is primarily derived from its allergy treatment segment, which generated DKK5.38 billion.Overview: EO Technics Co., Ltd. manufactures and supplies laser processing equipment worldwide, with a market cap of approximately 1.67 billion.Operations: The company generates revenue primarily from its Semiconductor Machine Division, which acc","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/zaka0IkqQV2sJCcfbX6qiA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/c5201eeaa7905447e59995740351e3e5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/zaka0IkqQV2sJCcfbX6qiA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/c5201eeaa7905447e59995740351e3e5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-stocks-may-trading-below-040703246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7110","AKBLF","CSC.AU"],"gpt_icon":0},{"id":"2492902434","title":"Positive results advance peanut tablet to phase II development","url":"https://stock-news.laohu8.com/highlight/detail?id=2492902434","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492902434?lang=en_us&edition=fundamental","pubTime":"2024-12-18 19:51","pubTimestamp":1734522660,"startTime":"0","endTime":"0","summary":"ALK’s peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding and efficacy.First patients in phase II to receive first doses imminently. Trial expected to complete in 2026.ALK  today announced positive interim results from its phase I/II clinical trial  for its investigational sublingual immunotherapy  tablet for the treatment of peanut allergy.This part of the trial, which involved approximately 30 patients, investigated safety and tolerability of multiple doses of the peanut tablet across the up-dosing regimen. Each patient received daily dosing for ten weeks. For all dose levels, the tablet was shown to be safe and tolerable. The vast majority of treatment-emergent side effects were transient, mild to moderate, local application site reactions. No serious adverse events and no cases of treatment emergent anaphylaxis were reported.Provided a successful phase II outcome, ALK intends to advance the peanut SLIT-tablet into","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/TFRWuPjwySPHeuzcZu7baA--~B/aD0zOTt3PTE0MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/848fac2aa05860966f3ec6e476ae2174","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/TFRWuPjwySPHeuzcZu7baA--~B/aD0zOTt3PTE0MjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/848fac2aa05860966f3ec6e476ae2174"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/positive-results-advance-peanut-tablet-115100248.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AKBLF","BK4007"],"gpt_icon":0},{"id":"2484937796","title":"Alk-Abello AS (AKBLF) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Improved Margins","url":"https://stock-news.laohu8.com/highlight/detail?id=2484937796","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484937796?lang=en_us&edition=fundamental","pubTime":"2024-11-19 09:02","pubTimestamp":1731978164,"startTime":"0","endTime":"0","summary":"Organic Revenue Growth: 18% across regions and product lines.Tapti Revenue Growth: 29% globally, 27% in Europe.EBIT Margin: Increased by 10 percentage points from 13% to 23% year-on-year.Revenue from Europe: Up 21% with double-digit growth in key markets.Tablet Sales Growth in Europe: 27% driven by higher volumes.North America Sales Growth: 3% overall, with tablet sales up 13%.International Markets Revenue Growth: 27%, with tablet revenue up 39%.Global Tablet Revenue Growth: 29% across all sales regions.Gross Margin: 64.3%, an improvement of more than 1 percentage point.Operating Profit : 886 million Danish Krona, a 91% improvement in local currencies.Free Cash Flow: Improved to 425 million Danish Krona.Full Year Revenue Growth Outlook: 14% to 16%.Full Year EBIT Margin Outlook: 19% to 21%.GuruFocus has detected 3 Warning Signs with CYRBY.Alk-Abello AS  reported an 18% organic revenue growth across regions and product lines in Q3.Alk-Abello AS  confirmed its full-year outlook, expecting","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qnCeb.7mr9hCRAnmkqBXYw--~B/aD02Mjt3PTIyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/5e2dae84a11396ec8cd9ba1db2a3d2fc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qnCeb.7mr9hCRAnmkqBXYw--~B/aD02Mjt3PTIyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/us.finance.gurufocus/5e2dae84a11396ec8cd9ba1db2a3d2fc"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alk-abello-akblf-q3-2024-010244391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AKBLF"],"gpt_icon":0},{"id":"2484926066","title":"3 Stocks That May Be Trading At A Discount Of Up To 41.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484926066","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484926066?lang=en_us&edition=fundamental","pubTime":"2024-11-18 13:02","pubTimestamp":1731906140,"startTime":"0","endTime":"0","summary":"In the current global market environment, uncertainty surrounding the incoming Trump administration's policies has contributed to volatility, with U.S. stocks experiencing a partial reversal of recent gains and sector returns showing significant variation. As investors navigate these fluctuations and consider potential policy impacts on corporate earnings, identifying stocks that may be undervalued can offer opportunities for those seeking value investments. A good stock in this context is one that not only shows potential for growth but also trades below its intrinsic value, presenting a possible discount in light of prevailing economic conditions.Overview: ALK-Abelló A/S is an allergy solutions company operating in Europe, North America, and internationally, with a market cap of DKK34.95 billion.Operations: The company's revenue segments include Pension , General Insurance Sweden , General Insurance Private , and General Insurance Commercial .","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/WVt2FvadDqexmfyC8nmCeA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/64306ded08622a838132aa4cadf007ad","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/WVt2FvadDqexmfyC8nmCeA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/64306ded08622a838132aa4cadf007ad"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/3-stocks-may-trading-discount-050220324.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AKBLF","GJNSY","GJNSF","BK4117"],"gpt_icon":0},{"id":"2482884197","title":"ARS Pharmaceuticals announces agreement with ALK to commercialize neffy","url":"https://stock-news.laohu8.com/highlight/detail?id=2482884197","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482884197?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:06","pubTimestamp":1731326762,"startTime":"0","endTime":"0","summary":"ARS Pharmaceuticals (SPRY) announced a licensing agreement with ALK-Abello A/S (AKBLF), that provides ALK exclusive rights to commercialize neffy, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-announces-agreement-with-alk-to-commercialize-neffy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ars-pharmaceuticals-announces-agreement-with-alk-to-commercialize-neffy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4008","BK4139","BK4007","SPRY","BK4585","BK4500","AKBLF","ALK","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AKBLF\",params:#limit:5,,,undefined,":[{"date":"2024-05-02","symbol":"AKBLF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1714636800000,"name":null,"time":"Pre-Market","dateTimestamp":1714622400000,"actualEps":null},{"date":"2022-11-10","symbol":"AKBLF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1668070800000,"name":null,"time":"Pre-Market","dateTimestamp":1668056400000,"actualEps":null},{"market":"US","date":"2022-08-11","symbol":"AKBLF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1660190400000,"reportTimeType":"","actualEps":null},{"date":"2022-05-12","symbol":"AKBLF","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1652342400000,"name":null,"time":"","dateTimestamp":1652328000000,"actualEps":null},{"market":"US","date":"2022-03-28","symbol":"AKBLF","defaultRemindTime":1648474200000,"type":"split","dateTimestamp":1648440000000,"forFactor":1,"toFactor":20,"ratio":0.05}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AKBLF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AKBLF\",market:\"US\",delay:false,,,undefined,":{}}}